AI Article Synopsis
- Palonosetron hydrochloride is an anti-emetic that acts as an antagonist of the 5-HT3 serotonin receptor, helping to prevent nausea and vomiting.
- It has a longer duration of action, making it effective for both acute and delayed nausea, especially in chemotherapy patients.
- The FDA has approved it for preventing and treating post-operative nausea and vomiting based on extensive literature searches conducted using resources like Google Scholar and PubMed.
Article Abstract
Many anti-emetics are used in clinical practice. Palonosetron hydrochloride is one of them. It is a novel, centrally acting antiemetic, and anti-nausea agent. This drug is an antagonist of serotonin receptor subtype 3 (5-HT3). This drug has longer duration of action which makes it useful in the prevention and treatment of acute and delayed onset of nausea and vomiting. This drug was initially used for chemotherapy induced nausea and vomiting. Federal drug agency (FDA) has approved it for prevention and treatment of post-operative nausea and vomiting. The literature search for this article was done using Google scholar and Pubmed using the terms "Palonosetron," "longer duration of action," "nausea," "vomiting," and "postoperative".
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4173575 | PMC |
| http://dx.doi.org/10.4103/0259-1162.128894 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing Compliance With Preoperative Fasting Guidelines: A Closed-Loop Quality Improvement Initiative to Optimize Patient Safety and Outcomes.
Cureus
December 2024
Cardiothoracic Surgery, Moscow Regional Research and Clinical Institute, Moscow, RUS.
Introduction Preoperative fasting is essential in surgical care to reduce the risk of pulmonary aspiration during anesthesia. International guidelines, such as those from the American Society of Anesthesiologists (ASA) and the European Society of Anaesthesiology (ESA), recommend fasting durations of six hours for solids and two hours for clear liquids. However, adherence to these guidelines often varies in clinical practice, leading to prolonged fasting times that can negatively impact patient outcomes, including dehydration, hypoglycemia, discomfort, and delayed recovery.
View Article and Find Full Text PDFWhile most pregnancies are affected by nausea and vomiting, hyperemesis gravidarum (HG) is at the severe end of the clinical spectrum and is associated with dehydration, undernutrition, and adverse maternal, fetal, and child outcomes. Herein we performed a multi-ancestry genome-wide association study (GWAS) of severe nausea and vomiting of pregnancy of 10,974 cases and 461,461 controls across European, Asian, African, and Latino ancestries. We identified ten significantly associated loci, of which six were novel ( , , , , , and and confirmed previous genome-wide significant associations with risk genes , , , and .
View Article and Find Full Text PDFEfficacy and Safety Analysis of Axitinib Combined with Sintilimab as Second-Line Treatment for Advanced Renal Cell Carcinoma: A Retrospective Study.
Arch Esp Urol
December 2024
Department of Emergency Surgery, Qingdao Eighth People's Hospital, 266000 Qingdao, Shandong, China.
Background: Targeted therapies, including axitinib, a vascular endothelial growth factor receptor inhibitor, and sintilimab, a programmed cell death protein-1 inhibitor, have shown promise in the treatment of advanced renal cell carcinoma (RCC). Although their individual efficacies have been demonstrated, the potential synergistic effects of combining these two agents are still being explored.
Methods: This study retrospectively analysed patients with advanced RCC admitted to our hospital from January 2022 to December 2023.
Efficacy and safety of ondansetron orally soluble pellicle for preventing moderate- to high-emetic risk chemotherapy-induced nausea and vomiting.
BMC Cancer
January 2025
Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 116 South Zuodaoquan Road, Wuhan, 430079, China.
Objective: Ondansetron orally soluble pellicle can serve as an alternative option for preventing nausea and vomiting in patients who receive chemotherapy. However, there is a lack of clinical evidence regarding ondansetron. This study aimed to explore the efficacy and safety of ondansetron in patients with malignant tumours who received chemotherapy drugs with a moderate-to-high emetic risk.
View Article and Find Full Text PDFEfficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials.
Ann Intern Med
January 2025
Centre of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital; Division of Experimental Medicine, McGill University; Department of Epidemiology, Biostatistics and Occupational Health, McGill University; Department of Medicine, McGill University; and Division of Cardiology, Jewish General Hospital/McGill University, Montreal, Quebec, Canada (M.J.E.).
Background: Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes.
Purpose: To assess the efficacy and safety of GLP-1 RAs and co-agonists for the treatment of obesity among adults without diabetes.
Data Sources: MEDLINE, Embase, and Cochrane CENTRAL from inception to 4 October 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!